By Connor Wallace
Senator Angus King (I-Maine) applauded a move by the Administration to implement a piece of Senator King’s bipartisan legislative efforts to require the disclosure of drug prices in advertising. The rule will help to empower patients, promote transparency, and lower prescription drug costs. “This new rule, which has significant bipartisan support, will bring much-needed accountability and transparency to prescription drug costs, so patients can fully understand what they’re being sold. The average American sees nine DTC prescription drug ads each day. For these reasons, most countries have banned DTC prescription drug advertising, with the United States and New Zealand being the only two developed countries that allow it.
Senators Angus King (I-Maine), Dick Durbin (D-Ill.) and Chuck Grassley (R-Iowa) urged their fellow members of Congress to stop caving to the wishes of Big Pharma. The amendment would help to empower patients, promote transparency, and lower prescription drug costs. The average American sees nine DTC prescription drug ads each day. For these reasons, most countries have banned DTC prescription drug advertising, with the United States and New Zealand being the only two developed countries that allow it. The Durbin-Grassley-King amendment was supported by the AARP, American Medical Association, American Hospital Association, Federation of American Hospitals, America’s Health Insurance Plans, BlueCross BlueShield Association, and the Campaign for Sustainable Rx Pricing.
